Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541576 | 1.00 | NNMT (0.36) | NNMTPOLBTDP1PLAUCYP11B1 | |
| SCHEMBL2541569 | 1.00 | NNMT (0.36) | NNMTPOLBTDP1PLAUCYP11B1 | |
| SCHEMBL2516681 | 0.80 | TXNRD1 (0.42) | — | |
| SCHEMBL2516684 | 0.80 | TXNRD1 (0.42) | — | |
| SCHEMBL2516685 | 0.80 | TXNRD1 (0.42) | — | |
| SCHEMBL4440181 | 0.73 | NNMT (0.33) | NNMTPOLBTDP1 | |
| SCHEMBL3058519 | 0.73 | TDP1 (0.51) | NNMTPOLBTDP1PLAU | |
| SCHEMBL14358203 | 0.73 | NNMT (0.54) | NNMTPOLBTDP1PLAUGAA | |
| SCHEMBL31663021 | 0.71 | NPSR1 (0.47) | NNMTPOLBTDP1GAA | |
| SCHEMBL4257399 | 0.71 | NPSR1 (0.47) | NNMTPOLBTDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379554-B1 | NAPHTHYRIDIN-2(1H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| US-8318940-B2 | Naphthyridin-2 (1 H)-one compounds useful as antibacterials | GLAXO GROUP LIMITED (GB) | 2012-11-27 | — | — | US | disclosed |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
| EP-2379554-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-10-26 | — | — | EP | disclosed |
| EP-2238135-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2010-10-13 | — | — | EP | disclosed |
| WO-2010081874-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
| WO-2009090222-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
| EP-2080761-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | RIF1, MRPL21, NAT1 | NNMT 1226/4885POLB 954/4885TDP1 2362/4885 |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | NAT1, RIF1, MRPL21 | NNMT 1883/4885POLB 860/4885TDP1 2318/4885 |
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | NRDC, NDC1, NANS | NNMT 32/4885POLB 1231/4885TDP1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.